• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Clinical benefit of switching from paclitaxel to docetaxel or vice versa in cutaneous angiosarcoma patients resistant to first taxane chemotherapy
The objective response rate, defined as the sum of complete response (CR) and partial response (PR) rates, was 16.7%. The disease control rate, defined as the sum of CR, PR, and stable disease rates, was 50%. The frequency of adverse events during the second taxane was the same between the two groups (p > 0.999). Our report suggests that CAS patients could benefit from the second taxane treatment if the tumor is resistant to the first taxane.PMID:37400887 | DOI:10.1111/1346-8138.16873
Source: Cancer Control - July 3, 2023 Category: Cancer & Oncology Authors: Satoru Yonekura Yuichiro Endo Hiroko Fujii Makiko Ishikawa Gyohei Egawa Kenji Kabashima Source Type: research

Is Hypoglycemia Secondary to Metastatic Retroperitoneal Sarcoma -A Therapeutic Challenge? Case Report and Review of Literature
Curr Probl Cancer. 2023 May 14;47(3):100961. doi: 10.1016/j.currproblcancer.2023.100961. Online ahead of print.ABSTRACTMost soft tissue sarcomas afflict the extremities; however, the retro peritoneum can also be affected rarely. Retroperitoneal sarcomas are relatively asymptomatic. Although tumor-induced hypoglycemia is rare in tumors other than insulinomas, extrapancreatic tumors are a subset that displays this phenomenon. The occurrence of hypo-insulinemic hypoglycemia with low GH and IGF-1 should prompt consideration of the secretion of a hypoglycemic substance impeding the secretion of insulin and GH, such as IGF-2 or ...
Source: Cancer Control - June 1, 2023 Category: Cancer & Oncology Authors: Rishi P Nair Atul Kumar Gupta Puneet Pareek Bharti Devnani Sandeep Kumar Bairwa Pawan K Garg Divya Aggarwal Smily Sharma Tushar Mittal Source Type: research

Poor Treatment Outcomes with Second-Line Chemotherapy in Advanced Synovial Sarcoma
CONCLUSION: Our exploratory study revealed that the response rate of second-line chemotherapy regimens for patients with synovial sarcoma was 9.4%. Therefore, there is an urgent need to develop more active therapeutic regimens for synovial sarcomas.PMID:35405680 | DOI:10.1159/000524500
Source: Oncology - April 11, 2022 Category: Cancer & Oncology Authors: Yuki Kojima Tatsunori Shimoi Takuji Seo Shu Yazaki Toshihiro Okuya Yohei Ohtake Hitomi S Okuma Akihiko Shimomura Tadaaki Nishikawa Maki Tanioka Kazuki Sudo Emi Noguchi Kenji Tamura Akihiko Yoshida Shintaro Iwata Eisuke Kobayashi Akira Kawai Yasuhiro Fujiw Source Type: research

Pages: 1  2  3  4  5  6  7  8